- Case report
- Open Access
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C
© Benedetto and Houston; licensee BioMed Central Ltd. 2006
- Received: 13 April 2006
- Accepted: 09 August 2006
- Published: 09 August 2006
There are no guidelines governing the concomitant use of recombinant human activated protein C (rhAPC) and deep venous thrombosis/pulmonary embolism (DVT/PE) prophylaxis in critically ill patients. It is unknown if rhAPC provides any protection against DVT/PE in this population of patients.
This report describes the first case of a radiographically demonstrated pulmonary embolism occurring in a patient receiving continuous therapeutic infusion of rhAPC.
The administration of rhAPC alone may not be sufficient DVT/PE prophylaxis in high risk patients. The risks associated with concomitant anticoagulation and rhAPC therapy are unknown. Further research is necessary to determine the safest and most effective regimen for DVT/PE prophylaxis in patients receiving rhAPC.
- Deep Venous Thrombosis
- Heparin Infusion
- Mesenteric Venous Thrombosis
- Prowess Trial
- FiO2 Ratio
Recombinant human activated protein C (rhAPC) has been demonstrated to improve mortality in critically ill patients with septic shock . It is thought that rhAPC exerts its effect via multiple mechanisms involving anti-inflammatory, antioxidative, antiapoptotic and anticoagulant pathways . The anticoagulant effect of rhAPC leads to a 2–3% incidence of severe bleeding complications in treated patients . This risk has led to the general practice of discontinuing the use of all other forms of anticoagulation, including deep venous thrombosis (DVT) prophylaxis, when rhAPC is used. It is unknown what DVT or pulmonary embolism (PE) prophylaxis is safe and appropriate in patients receiving rhAPC. Further, it is not known if rhAPC alone provides any protection against DVT/PE. We present a case report of a patient who developed a new, documented PE while receiving a continuous infusion of rhAPC.
On hospital day two, the patient developed increasing abdominal tenderness which was associated with fevers up to 39.5 degrees Celsius and acute renal failure. Surgery was consulted and recommended urgent operative exploration. Upon exploration the patient was found to have mesenteric venous thrombosis with a segment of ischemic small bowel. He underwent small bowel resection and was returned to the intensive care unit for continued resuscitation. At this time a heparin infusion was initiated given the patient's known factor XII deficiency and demonstrated mesenteric venous thrombosis. His partial thromboplastin time (PTT) was maintained between 60 and 80 seconds. The following day he had not improved; he was returned to the operating room where a second segment of ischemic bowel was discovered and further resection was performed. The patient again returned to the intensive care unit in critical condition requiring pressor support with levophed and continued ventilatory support with a PaO2 to FiO2 ratio of 180. At this point he was evaluated and found to be a candidate for rhAPC. This was initiated six hours after the completion of his operation. Due to concerns about potential bleeding complications, the heparin infusion was discontinued when the rhAPC was started. At the time of heparin discontinuation the patients PTT was 82 seconds and he had no clinical evidence of DVT or PE. His activated protein C level at that time was less than 10.
Critically ill patients are known to be at high risk for the development of DVT/PE with a rate of thromboembolic complications ranging between 9% and 29% depending on the specific population studied [3–6]. Multiple clinical trials have demonstrated that DVT/PE prophylaxis improves clinical outcomes in the critically ill [7, 8]. The Society of Critical Care Medicine guidelines for the treatment of patients with sepsis currently recommends that all critically ill patients receive DVT/PE prophylaxis with either subcutaneous heparin or low dose low molecular weight heparin unless otherwise contraindicated .
Whether administration of rhAPC should be a contraindication to the administration of DVT/PE prophylaxis with subcutaneous or low molecular weight heparin is not known. The PROWESS trial (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) offers some data on this subject. Subgroup analysis of mortality rates according to exposure to heparin in the PROWESS trial raised the possibility of a heparin/rhAPC drug interaction . The relative risk of 28-day all-cause mortality was increased in the group who received both heparin and rhAPC as compared to those who received only rhAPC. This increased relative risk of mortality was not due to an increase in bleeding complications in the heparin/rhAPC group, raising the possibility that heparin might reduce the efficacy of rhAPC. Subsequent biological data has demonstrated that heparin increases the affinity between native APC and alpha-1-proteinase inhibitor and a plasma protein C inhibitor, both of which decrease native APC activity . The in-vivo effect of heparin on rhAPC binding with alpha-1-proteinase inhibitor and plasma protein C inhibitor is not known. Further confounding this issue is the fact that the presence of the heterozygous mutation for the factor V leyden mutation does not seem to impact the effect of rhAPC .
Bleeding is the most significant complication associated with rhAPC with a 1–2% incidence of significant bleeding complications. At the doses used for DVT/PE prophylaxis neither subcutaneous nor low dose low molecular weight heparin have been associated with an increased risk of serious bleeding complications. Low dose low molecular weight heparin has, however, been associated with an increased rate of wound hematomas in post surgical patients. It is not known if concomitant administration of rhAPC and either subcutaneous or low dose low molecular weight heparin produces a synergistic increase on the risk of significant bleeding complications.
It is known that the activity of native activated protein C is diminished in critically ill patients . It is also known that patients with congenitally low levels of native protein C activity are prone to both micro and macrovascular thrombosis . Diminished levels of native protein C activity may play a role in the increased risk of DVT/PE demonstrated in critically ill patients. Modulation of this hypercoagulable state has been hypothesized to be the primary mechanism by which rhAPC exerts its beneficial effects. It is also thought to be this pathway that leads to the increased bleeding risk associated with its use. What impact this pathway has on DVT/PE risk is unclear. One animal study has demonstrated that the administration of rhAPC prevents thrombin induced DVT/PE in mice . The ability of rhAPC to prevent the development of DV/PE in this very high risk animal model is encouraging but the clinical relevance of this has not been elucidated.
There are also several other confounding factors that become relevant when dealing with the issue of rhAPC use and concomitant DVT/PE prophylaxis in individual critically ill patients. The kinetics of native protein C activity varies greatly between individual patients . While the activity of native activated protein C has been demonstrated to decrease in some critically ill patients, this decrease is not seen in every patient. Furthermore, even in those patients who do have decreased levels of native activated protein C activity, certain patients have earlier rebound of native protein C activity while others may have prolonged suppression of activity. These variations in individual native activated protein C kinetics could lead to a wide variation of the degree of anticoagulation produced by rhAPC administration. Further, individual abnormalities of the coagulation cascade, whether acquired or genetic, are being identified with increasing frequency in the general population . It follows that these abnormalities occur with a similar frequency in the critically ill patient population as well. These factors, and others, will need to be more clearly defined in order to determine each patient's individual risk of DVT/PE and potential benefit or harm gained from the use of rhAPC.
In conclusion, this is the first known case report of a radiographically documented PE occurring in a patient receiving continuous infusion of rhAPC. This case suggests that rhAPC alone may not be sufficient DVT/PE prophylaxis in high risk patients. The risks associated with concomitant anticoagulation and rhAPC therapy are unknown. Further research is necessary to determine the safest and most effective regimen for DVT/PE prophylaxis in patients receiving rhAPC.
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garner GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.View ArticlePubMedGoogle Scholar
- Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated by protein C pathway. Science. 2002, 296: 1880-1882. 10.1126/science.1071699.View ArticlePubMedGoogle Scholar
- Pingleton SK, Bone RC, Pingleton WW, Ruth WE: Prevention of pulmonary emboli in a respiratory intensive care unit: efficacy of low-dose heparin. Chest. 1981, 79: 647-650.View ArticlePubMedGoogle Scholar
- Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982, 10: 448-450.View ArticlePubMedGoogle Scholar
- Halkin H, Goldberg J, Modan M: Reduction in general medical inpatients by low dose heparin prophylaxis. Ann Int Med. 1982, 96: 561-565.View ArticlePubMedGoogle Scholar
- Hirsch DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. J Am Med Assoc. 1995, 274: 335-337. 10.1001/jama.274.4.335.View ArticleGoogle Scholar
- Belch JJ, Lowe GD, Ward AG: Prevention of deep venous thrombosis in medical patients by low-dose heparin. Scott Med J. 1981, 26: 115-117.PubMedGoogle Scholar
- Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Eng J Med. 1999, 341: 793-800. 10.1056/NEJM199909093411103.View ArticleGoogle Scholar
- Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32: 858-871. 10.1097/01.CCM.0000117317.18092.E4.View ArticlePubMedGoogle Scholar
- Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: Data from the PROWESS trial. Intensive Care Med. 2003, 29: 894-903.PubMedGoogle Scholar
- Linder R, Frebelius S, Jansson K: Inhibition of the endothelial cell-mediated generation of activated protein C by direct and antithrombin dependant thrombin inhibitors. Blood Coagul Fibrinolysis. 2003, 14: 139-146. 10.1097/00001721-200302000-00004.View ArticlePubMedGoogle Scholar
- Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF: Survival advantage associated with heterogeneous factor V leiden mutation in patients with severe sepsis and mouse endotoxemia. Blood. 2003, 102: 3085-3092. 10.1182/blood-2003-06-1789.View ArticlePubMedGoogle Scholar
- Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR: Low levels of Protein C are associated with poor outcomes in severe sepsis. Chest. 2001, 120: 915-922. 10.1378/chest.120.3.915.View ArticlePubMedGoogle Scholar
- Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Eng J Med. 1999, 340: 1555-1564. 10.1056/NEJM199905203402007.View ArticleGoogle Scholar
- Gresele P, Stefania M, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M: Activated human protein C prevents thrombin-induced thromboembolism in mice. J Clinical Investigation. 1998, 101: 667-676.View ArticleGoogle Scholar
- Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D: Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood. 2004, 104: 3958-3964. 10.1182/blood-2004-03-1203.View ArticlePubMedGoogle Scholar
- Nicolaes GA, Dhalback B: Activated protein C resistance (FV Leiden) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am. 2003, 17: 37-61. 10.1016/S0889-8588(02)00097-7.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.